ClinicalBiostats

Clinical Trials

See the methods at work.

Statistical analyses of real clinical trials: design, endpoints, results and interpretation, organized by therapeutic area and linked to the methods behind them.

11,187 trials analyzed so far

Trials that use: Poisson regression

New to this method? Read the tutorial →

147 results

Post-Market Evaluation of the EVO ICL: Complete Statistical AnalysisIndependent statistical analysis of Post-Market Evaluation of the EVO ICL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05538754).Phase NAResults postedn = 205NCT05538754
Preventing Sexual Transmission of HIV With Anti-HIV Drugs: Complete Statistical AnalysisIndependent statistical analysis of Preventing Sexual Transmission of HIV With Anti-HIV Drugs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00074581).Phase 3Results postedn = 3,526NCT00074581
PRINTOJDMTRIndependent statistical analysis of Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00323960).Phase 3Results postedn = 139NCT00323960
PRONTO-PumpIndependent statistical analysis of A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes: primary endpoint results, effect estimate with…Phase 3Results postedn = 49NCT03433677
PRONTO-T2DIndependent statistical analysis of A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 933NCT03214380
PROTEKTIndependent statistical analysis of Kaletra in Combination With Antiretroviral Agents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01076179).Phase NAResults postedn = 502NCT01076179
PURPOSE 2Independent statistical analysis of PURPOSE 2, a randomized phase 3 trial of lenacapavir for HIV pre-exposure prophylaxis, including its rate-based primary analyses, Poisson regression, Wald testing, confidence intervals, and statistical interpretation.Phase 3Results postedn = 3,292NCT04925752
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism: Complete Statistical AnalysisIndependent statistical analysis of RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 7,797NCT02596230
REDUCEhfIndependent statistical analysis of Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (HF) (REDUCEhf): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 442NCT00354159
RESOLVEIndependent statistical analysis of Tailored Non-Pharmacotherapy Services for Chronic Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04523714).Phase NAResults postedn = 2,333NCT04523714
RESPIRE 1Independent statistical analysis of RESPIRE 1, a randomized phase 3 trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis, including time-to-exacerbation and exacerbation-rate analyses.Phase 3Results postedn = 416NCT01764841
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS): Complete Statistical AnalysisIndependent statistical analysis of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS): primary endpoint results, effect estimate with confidence…Phase 4Results postedn = 2,354NCT01443845
Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS): Complete Statistical AnalysisIndependent statistical analysis of Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 250NCT00614523
RVDDIndependent statistical analysis of Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 74NCT00724568
Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of Bleeding: Complete Statistical AnalysisIndependent statistical analysis of Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of Bleeding: primary endpoint results,…Phase NAResults postedn = 120,722NCT05471505
Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data: Complete Statistical AnalysisIndependent statistical analysis of Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data: primary endpoint results, effect estimate with confidence…Phase NAResults postedn = 77,814NCT05438888
Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 393NCT02357420
SPIRE-1Independent statistical analysis of The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 16,784NCT01975376
SPIRE-2Independent statistical analysis of The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 10,564NCT01975389
SQ53 Disinfectant Wipes for Prevention of CRBSI: Complete Statistical AnalysisIndependent statistical analysis of SQ53 Disinfectant Wipes for Prevention of CRBSI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04822467).Phase NAResults postedn = 59NCT04822467
STANDIndependent statistical analysis of Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 253NCT03814746
STARIndependent statistical analysis of Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 326NCT00573443
Study Of “Continuous Use” Of Celecoxib Vs. “Usual or Intermittent Use”: Complete Statistical AnalysisIndependent statistical analysis of Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use": primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 875NCT00139776
Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF): Complete Statistical AnalysisIndependent statistical analysis of Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02139306).Phase 3Results postedn = 279NCT02139306
Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants: Complete Statistical AnalysisIndependent statistical analysis of Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1Results postedn = 32NCT04987333
Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures: Complete Statistical AnalysisIndependent statistical analysis of Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00594945).Phase 2Results postedn = 45NCT00594945
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos): Complete Statistical AnalysisIndependent statistical analysis of Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos): primary endpoint results, effect estimate…Phase 3Results postedn = 8,588NCT02465567
Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals’ Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older: Complete Statistical AnalysisIndependent statistical analysis of Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older: primary endpoint results, effect estimate with…Phase 3Results postedn = 16,165NCT01165177
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Herpes Zoster Vaccine GSK1437173A: Complete Statistical AnalysisIndependent statistical analysis of Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 1,877NCT01610414
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin: Complete Statistical AnalysisIndependent statistical analysis of Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 304NCT01517373
Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC): Complete Statistical AnalysisIndependent statistical analysis of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC): primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 317NCT00267748
SUPERNOVAIndependent statistical analysis of the randomized phase 2/3 SUPERNOVA trial of AZD3152 and AZD7442 for prevention of COVID-19, including non-inferiority, superiority, Poisson regression, ANOVA, safety, and interpretation of reported results.Phase 2/3Results postedn = 3,882NCT05648110
SWIFT-1Independent statistical analysis of Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 395NCT04719832
SWITCH 2Independent statistical analysis of A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes: primary endpoint results, effect estimate…Phase 3Results postedn = 721NCT02030600
T1GERIndependent statistical analysis of A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 84NCT02846545
TECTONICSIndependent statistical analysis of Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 79,560NCT03923699
Testing an Implementation Science Tool to Increase Cervical Cancer Screening in Mombasa, Kenya: Complete Statistical AnalysisIndependent statistical analysis of Testing an Implementation Science Tool to Increase Cervical Cancer Screening in Mombasa, Kenya: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 20NCT03514459
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC): Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC): primary endpoint results,…Phase 3Results postedn = 544NCT03811002
The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome: Complete Statistical AnalysisIndependent statistical analysis of The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase EARLY_1Results postedn = 17NCT01102270
TICSIndependent statistical analysis of Tick-borne Illness and Clothing Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01454414).Phase NAResults postedn = 159NCT01454414
TIDE-asthmaIndependent statistical analysis of Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 437NCT05421598
TRILOGYIndependent statistical analysis of Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 1,368NCT01917331
TULIP SLE LTEIndependent statistical analysis of Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 559NCT02794285
V-EXTRA-CVDIndependent statistical analysis of A Nurse-led Intervention to Extend the Veteran HIV Treatment Cascade for Cardiovascular Disease Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 305NCT04545489
VMBIndependent statistical analysis of Rwanda Vaginal Microbiota Restoration Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02459665).Phase NAResults postedn = 68NCT02459665
WARCEFComplete statistical analysis of the WARCEF trial, comparing warfarin with aspirin in patients with reduced cardiac ejection fraction, including trial design, time-to-event endpoints, Cox and Poisson regression, reported results, safety, and statistical…Phase 3Results postedn = 2,305NCT00041938
YOGAMAT-IIIndependent statistical analysis of Optimization and Multi-Site Feasibility of Yoga for Chronic Pain in People in YOGAMAT-II - Phase II: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 192NCT04641221